Document is current
Any future updates will be listed below
-
Authors
Jaakkola, Elina
Ijas, Jani
Joutsa, Juho
Vahlberg, Tero
Myller, Elina
Eklund, Mikael
Nuuttila, Simo
Murtomäki, Kirsi
Mertsalmi, Tuomas
Levo, Reeta
Noponen, Tommi
Ihalainen, Toni
Scheperjans, Filip
Kaasinen, Valtteri
-
Funding
Funding for this research was provided by:
Suomen Parkinson-säätiö
Turun Yliopisto
Päivikki ja Sakari Sohlbergin Säätiö
Turun Yliopistollisen Keskussairaalan Koulutus- ja Tutkimussäätiö
Suomen Kulttuurirahasto
- License Information
-
More Information
Article History
Received: 9 April 2025
Accepted: 7 August 2025
First Online: 14 August 2025
Competing interests
: E.J. reports grants from the Finnish Medical Foundation and the Finnish Parkinson Foundation. J.J. reports research grants from the Sakari Sohlberg’s Foundation, Finnish Research Council, Finnish Medical Foundation, Sigrid Juselius Foundation, Finnish Foundation for Alcohol Studies, University of Turku and Turku University Hospital; conference travel support from Insightec, AbbVie, and Abbott; consulting for Teva Finland, Summaryx, and Adamant Health; lecturer honoraria from Addiktum, Nordic Infucare, Lundbeck, and Novartis; acting as an advisory board member for Teva Finland; and stock ownership of Neurologic Finland and Suomen Neurolaboratorio. ME has received grants from The Finnish Parkinson Foundation, The Finnish Medical Foundation, Maire Taponen Foundation, The Finnish Brain Foundation, Orion Research Foundation and Turku University Hospital (VTR, internal research funding). KM reports grants from Maire Taponen Foundation, the Hospital District of Helsinki and Uusimaa and the Finnish Parkinson Foundation. TN reports lecturer honoraria (GE Healthcare) and research grants (GE Healthcare and Turku University Hospital). FS reports consultancies (Abbvie, Axial Biotherapeutics, Orion Pharma, Teva, Adamant Health), honoraria (Abbvie, GE Healthcare, Merck, Teva, Bristol Myers Squibb, Sanofi, Biocodex, Biogen), grants (Emil Aaltonen Foundation, Konung Gustav V:s och Drottning Victorias Stiftelse, Olvi Foundation, Yrjö Jahnsson Foundation, Stockmann Foundation, Sigrid Juselius Foundation, Research Council of Finland, Hospital District of Helsinki and Uusimaa, Renishaw, Orion Pharma, Abbvie), travel expenses (Lundbeck, NordicInfucare), stock (NeuroInnovation Oy, NeuroBiome Oy, Axial Biotherapeutics). V.K. reports advisory boards (Abbvie, Nordic Infucare AB), honoraria (Orion Pharma, Nordic Infucare AB, Abbvie, Eisai, Lundbeck, Teva, Bial), travel expenses (Nordic Infucar AB), grants (the Päivikki and Sakari Sohlberg Foundation, the Finnish Cultural Foundation, the Finnish Parkinson Foundation, the Turku University Foundation, Turku University Hospital (VTR-funds).
